Emicizumab in Hemophilia A.
作者信息
Buckner Tyler W, Watson Crystal, Recht Michael
机构信息
University of Colorado School of Medicine, Aurora, CO.
American Thrombosis and Hemostasis Network, Rochester, NY
出版信息
N Engl J Med. 2020 Feb 20;382(8):785-786. doi: 10.1056/NEJMc1916299.
PMID:32074441
Abstract
摘要
相似文献
1
Emicizumab in Hemophilia A.艾美赛珠单抗治疗甲型血友病
N Engl J Med. 2020 Feb 20;382(8):785-786. doi: 10.1056/NEJMc1916299.
2
Emicizumab for the prevention of bleeds in hemophilia A.依库珠单抗预防 A 型血友病出血
Expert Opin Biol Ther. 2019 Aug;19(8):753-761. doi: 10.1080/14712598.2019.1626370. Epub 2019 Jun 13.
3
Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.在血友病抑制剂管理中实施依库珠单抗：应在耐受后开具依库珠单抗。
Blood Adv. 2018 Oct 23;2(20):2780-2782. doi: 10.1182/bloodadvances.2018015842.
4
Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.艾美赛珠单抗用于常规预防以防止甲型血友病患者出血发作。
Drugs Today (Barc). 2018 Oct;54(10):591-600. doi: 10.1358/dot.2018.54.10.2869771.
5
Emicizumab in Hemophilia A.艾美赛珠单抗治疗甲型血友病
N Engl J Med. 2020 Feb 20;382(8):785. doi: 10.1056/NEJMc1916299.
6
Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.艾美赛珠单抗（Hemlibra）用于A型血友病的皮下预防治疗。
Med Lett Drugs Ther. 2019 May 20;61(1572):77-79.
7
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.艾美赛珠单抗预防治疗伴有抑制物的甲型血友病。
N Engl J Med. 2017 Nov 30;377(22):2193-4. doi: 10.1056/NEJMc1712683.
8
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.伴有抑制物的甲型血友病患者中艾美赛珠单抗预防治疗
N Engl J Med. 2017 Nov 30;377(22):2193. doi: 10.1056/NEJMc1712683.
9
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.艾美赛珠单抗用于预防伴有抑制物的甲型血友病。
N Engl J Med. 2017 Nov 30;377(22):2194-2195. doi: 10.1056/NEJMc1712683.
10
Emicizumab in Hemophilia A. Reply.用于A型血友病的艾美赛珠单抗。回复。
N Engl J Med. 2020 Feb 20;382(8):786. doi: 10.1056/NEJMc1916299.
引用本文的文献
1
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.用于预防先天性 A 型或 B 型血友病患者出血的非凝血因子治疗方法。
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
2
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.建立评估先天性血友病 A 患者死亡率的框架及其在不良事件报告数据库中的应用。
J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):21-31. doi: 10.1111/jth.15186.
Zotero 插件